Headline
The latest stories from AHA Today.
The number of health care providers with waivers to prescribe buprenorphine for opioid use disorder increased 19% between October 2021 and September 2022 to 132,005, HHS announced.
HIPAA-regulated entities are not permitted to use online tracking technologies in a manner that would result in impermissible disclosures of protected health information to tracking technology vendors or any other violation of the HIPAA rules, HHS' Office for Civil Rights reminded covered entities…
The Health Resources and Services Administration has released Maternity Care Target Area weighted scores for Primary Care Health Professional Shortage Areas experiencing a shortage of maternity health care professionals.
The National Quality Forum’s Measure Applications Partnership is accepting public comment through Dec. 7 at 6 p.m. ET on 52 performance measures CMS is considering for use in Medicare public reporting and payment programs.
AHA sent a letter to Sen. Mark Warner, co-chair of the Senate Cybersecurity Caucus, responding to his recent report on policy options to address cybersecurity challenges in the health care field.
Learn how New York’s Mount Sinai Health System took on the task of addressing its community’s health inequities while managing the myriad challenges brought on by the COVID-19 pandemic, an effort that captured AHA's 2022 Equity of Care Award.
AHA today urged the Centers for Medicare & Medicaid Services not to establish a national directory of health care providers and services (NDH) at this time.
The Centers for Medicare & Medicaid Services seeks public input on topics related to essential health benefits — items and services that all non-grandfathered health plans in the individual and small group markets must cover under the Affordable Care Act
AHA today urged the Drug Enforcement Administration to release its proposed rules outlining a special registration process for prescribing medically necessary controlled substances via telehealth after the COVID-19 public health emergency; provide an interim plan to support continuity of care if…
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the United States because it is not expected to neutralize the predominating BQ.1 and BQ.1.1. omicron subvariants.